XT
RARE icon

XTX Topco’s Ultragenyx Pharmaceutical RARE Stock Holding History

XTX Topco’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$500K Sell
23,887
-96,109
-80% -$2.16M 0.01% 2054
2025
Q4 		$2.76M Buy
119,996
+105,622
+735% +$3.47M 0.07% 380
2025
Q3 		$432K Sell
14,374
-22,846
-61% -$685K 0.02% 1185
2025
Q2 		$1.35M Buy
37,220
+5,440
+17% +$196K 0.06% 505
2025
Q1 		$1.15M Buy
31,780
+20,532
+183% +$854K 0.06% 484
2024
Q4 		$473K Sell
11,248
-3,381
-23% -$168K 0.04% 807
2024
Q3 		$813K Buy
14,629
+7,134
+95% +$363K 0.06% 524
2024
Q2 		$308K Sell
7,495
-5,726
-43% -$244K 0.03% 941
2024
Q1 		$617K Buy
13,221
+5,815
+79% +$274K 0.08% 363
2023
Q4 		$354K Sell
7,406
-5,613
-43% -$218K 0.08% 495
2023
Q3 		$464K Buy
13,019
+3,670
+39% +$145K 0.08% 449
2023
Q2 		$431K Sell
9,349
-1,820
-16% -$84.4K 0.08% 468
2023
Q1 		$448K Buy
11,169
+5,876
+111% +$252K 0.09% 364
2022
Q4 		$245K Buy
+5,293
New +$208K 0.05% 713

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

XTX Topco's RARE Position: Q1 2026 in Review

XTX Topco reduced its Ultragenyx Pharmaceutical (RARE) stake by 80% in Q1 2026, selling an estimated $2.16M and leaving 23,887 shares worth $500K. The position accounts for 0.01% of the portfolio, ranked #2054.

XTX Topco first reported a position in RARE in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.76M in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • XTX Topco held 23,887 shares of Ultragenyx Pharmaceutical worth $500K as of Q1 2026.
  • XTX Topco sold 96,109 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.16M.
  • Ultragenyx Pharmaceutical made up 0.01% of XTX Topco's portfolio in Q1 2026, its #2054 holding.
  • XTX Topco first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and has held it in 14 quarters since.
  • XTX Topco's Ultragenyx Pharmaceutical position peaked at $2.76M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.